Moynam Ekte Heredeibona, Aroun Abdel Nassir, Bejendo Dan-Houron, Héritier Obed Lango, Christelle Luce Bobossi, Coretha Bokia Baguida, Ernest Lango-Yaya, Boniface Koffi, Emile Minyaka & Romaric NzoumbouBoko·Microbiology Research Journal International·2026
Background: Artemisinin-based combination therapies (ACTs) are the cornerstone of malaria treatment. However, partial artemisinin resistance associated with mutations in the Plasmodium falciparum Pfkelch13 propeller domain threatens malaria control efforts. The C580Y substitution...
Open access
Research Article10.9734/mrji/2026/v36i61751
The Plasmodium falciparum chloroquine resistance transporter (PfCRT) is localised on the parasite digestive vacuole, an organelle that maintains an acidic lumen. Here we demonstrated the isolation of HEK-293F cells stably expressing wild type 3D7 and mutant Pfcrt alleles. Immuno-...
Open access
Research Article10.9734/mrji/2021/v31i1030352
Artemisinin-based combination therapy (ACT) is the first-line therapy in most malaria endemic countries. An impressive 47% reduction in the global mortality rate between 2000 and 2013 has been achieved by ACT and artemisinin (ART) monotherapy. However, artemisinin resistance (AR)...
Open access
Research Article10.9734/BMRJ/2015/18776
Malaria is caused by the protozoan parasites of genus Plasmodium. Plasmodium falciparum is the most common cause of malaria in Africa and South-East Asia. In India, Plasmodium vivax has been the primary pathogen responsible for malaria, even though Plasmodium falciparum cases are...
Open access
Research Article10.9734/BMRJ/2015/10267